亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study

医学 中止 内科学 临床终点 不利影响 实体瘤疗效评价标准 临床研究阶段 黑色素瘤 无进展生存期 肿瘤科 化疗 外科 胃肠病学 临床试验 癌症研究
作者
Chuanliang Cui,Yu Chen,Zhiguo Luo,Zhengyun Zou,Yu Jiang,Hongming Pan,Qingxia Fan,Jianfu Zhao,Qing Xu,Renbing Jiang,Xuan Wang,Taiyang Ma,Zhen Guo,Lu Si,Zhihong Chi,Xinan Sheng,Yiwei Dou,Qian Tan,Di Wu,Jun Guo
出处
期刊:BMC Cancer [BioMed Central]
卷期号:23 (1) 被引量:8
标识
DOI:10.1186/s12885-022-10473-y
摘要

Abstract Background Pucotenlimab is a novel recombinant humanized anti-PD-1 (Programmed death-1) monoclonal antibody, which belongs to the human IgG4/kappa subtype, and can selectively block the binding of PD-1 with its ligands PD-L1 and PD-L2. Methods In this phase 2 trial, patients with locally advanced or metastatic melanoma who had failed conventional treatment (chemotherapy, targeted therapy, interferon, IL-2, et al.) were recruited. The patients were administrated with Pucotenlimab of 3 mg/kg every 3 weeks until disease progression, intolerable toxicity, or treatment discontinuation for any other reasons. The primary endpoint was the overall response rate (ORR). The secondary endpoints were disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and toxicity. Results One-hundred and nineteen patients were enrolled and followed up for 19.32 (ranging from 15.901 to 24.608) months by the cutoff date of July 30 th , 2021. The ORR was 20.17% (24/119, 95% CI, 13.370%-28.506%) based on both independent review committee (IRC) and the investigator’s assessment per RECIST v1.1. The median PFS were 2.89 (95% CI, 2.037–4.074) months and 2.46 (95% CI, 2.004–4.008) months based on IRC and investigator’s assessment, respectively, per RECIST v1.1. The median OS was 16.59 (95% CI, 13.963–26.973) months. Treatment-related adverse events (TRAEs) occurred in 77.3% (92/119) of the patients. The incidence of Grade ≥ 3 TRAEs was 15.1% (18/119). In addition, none of the patients died because of TRAEs. As for biomarker analysis, Eotaxin (CCL11) and MCP-1 (CCL2) were related to treatment response, while TNF-α and VEGF were related to treatment failure. Conclusions Pucotenlimab as a ≥ 2 nd line therapy showed promising efficacy and tolerable toxicity for patients with locally advanced or metastatic melanoma. Trial registration Clinicaltrials.gov Identifier: NCT04749485 (registered retrospectively on 11/02/2021).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lv发布了新的文献求助10
刚刚
冉亦完成签到,获得积分10
4秒前
WGS完成签到,获得积分10
5秒前
科研通AI2S应助科研通管家采纳,获得10
6秒前
华仔应助科研通管家采纳,获得20
6秒前
吉吉吉完成签到 ,获得积分10
8秒前
9秒前
阿九发布了新的文献求助10
14秒前
大胆的小懒猪完成签到 ,获得积分10
16秒前
111完成签到 ,获得积分10
17秒前
19秒前
yx_cheng应助001az采纳,获得30
19秒前
20秒前
miles完成签到,获得积分10
23秒前
简单山水发布了新的文献求助10
26秒前
Yina完成签到 ,获得积分10
48秒前
友好胜完成签到 ,获得积分10
51秒前
田様应助滴滴哒采纳,获得10
54秒前
苔原猫咪甜甜圈完成签到,获得积分10
55秒前
研友_ngkyGn应助Long采纳,获得10
55秒前
LJ_scholar完成签到,获得积分10
59秒前
斯文败类应助Ansaista采纳,获得10
1分钟前
善学以致用应助简单山水采纳,获得10
1分钟前
1分钟前
淡定的思松完成签到 ,获得积分10
1分钟前
滴滴哒发布了新的文献求助10
1分钟前
1分钟前
月亮完成签到 ,获得积分10
1分钟前
爹爹完成签到,获得积分10
1分钟前
爹爹发布了新的文献求助10
1分钟前
故意的山河完成签到,获得积分10
1分钟前
轻松的惜芹应助sss采纳,获得10
1分钟前
1分钟前
快乐顽童完成签到,获得积分10
1分钟前
1分钟前
1分钟前
醉熏的灵完成签到 ,获得积分10
1分钟前
wangdong完成签到,获得积分0
1分钟前
fengyl完成签到,获得积分20
1分钟前
姜忆霜完成签到 ,获得积分10
1分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990012
求助须知:如何正确求助?哪些是违规求助? 3532049
关于积分的说明 11256153
捐赠科研通 3270925
什么是DOI,文献DOI怎么找? 1805123
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809216